GlassScriptPhysician profile
Tyler J Kostecki
NPI 1598275562
$5,803.60
in general payments reported to CMS, 2019-2025
36 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,076 · 2022: $1,436 · 2023: $1,226 · 2024: $971 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,292.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,329.36 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $993.17 | 2021-2025 | |
| Amgen INC. | $520.92 | 2021-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $454.29 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $415.58 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $297.02 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $295.06 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Corcept Therapeutics | $154.81 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $137.52 | 2021-2023 | |
| Janssen Biotech, INC. | $127.04 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $110.51 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company LTD. | $85.48 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.92 | 2022-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $81.77 | 2024-2025 | Spravato |
| Jazz Pharmaceuticals INC. | $73.59 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $71.40 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $66.42 | 2022 | |
| Neuronetics, INC. | $48.49 | 2023 | Neurostar Tms Therapy System |
| Amneal Pharmaceuticals LLC | $46.06 | 2022-2023 | Unithroid |
| Madrigal Pharmaceuticals | $41.13 | 2024 | Resmetirom |
| Biohaven Pharmaceuticals, INC. | $39.90 | 2021 | |
| Novartis Pharmaceuticals Corporation | $35.68 | 2022 | |
| Bausch Health US, LLC | $33.28 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $30.16 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $29.81 | 2023 | Rexulti |
| Astellas Pharma US INC | $26.18 | 2023 | Veozah |
| Exact Sciences Corporation | $22.38 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.65 | 2022 | |
| Horizon Therapeutics Plc | $19.94 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.56 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $17.45 | 2025 | Gemtesa |
| Evoke Pharma, INC. | $16.35 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.42 | 2023 | Eliquis |
| Intercept Pharmaceuticals, INC. | $15.13 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.08 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Kostecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.